# Real-World Ibrexafungerp Use Patterns Among Patients with Commercial Health Insurance, United States, 2021–2023

## TL;DR

This study examines how a new antifungal drug, ibrexafungerp, was used in real-world settings for treating vaginal yeast infections in the U.S.

## Contribution

The study provides real-world usage patterns and safety data for ibrexafungerp, a new antifungal medication for vulvovaginal candidiasis.

## Key findings

- Most patients receiving ibrexafungerp were also prescribed other antifungal treatments like fluconazole.
- Only 2.9% of patients experienced potential side effects related to ibrexafungerp.
- Ibrexafungerp was primarily used as a non-first-line treatment for vulvovaginal candidiasis.

## Abstract

Vulvovaginal candidiasis (VVC) is a common gynecological complaint. Ibrexafungerp (brand name: Brexafemme®) is a new, first-in-class oral antifungal medication approved as a 1-day treatment for VVC and as a monthly treatment to reduce frequency of recurrent VVC.

This article describes characteristics of patients who received ibrexafungerp and potential ibrexafungerp-related side effects in order to help inform optimal future use of this medication.

We used a large, national commercial health insurance claims database (the MerativeTM MarketScan® Commercial/Medicare Database) to identify female patients with one or more outpatient ibrexafungerp prescription during 1 July 2021 to 31 December 2023. We examined patient demographic characteristics, medical conditions and medications, type of healthcare provider seen, diagnostic testing performed, and potential ibrexafungerp side effects.

Among 1368 female patients who received ibrexafungerp, most were also prescribed fluconazole or topical antifungals (84.7%) or had one or more vaginitis/vulvitis-related healthcare visit (76.9%) in the previous year. Few patients (2.9%) experienced a potential ibrexafungerp-related side effect.

Our results suggest that ibrexafungerp was generally used as non-first-line treatment for VVC.

The online version contains supplementary material available at 10.1007/s40801-025-00513-x.